用于局部晚期或转移性非小细胞肺癌患者的二线或三线治疗。 用于治疗不可切除或转移性微卫星高度不稳定型(MSI-H)或错配修复基因缺陷型(dMMR)的成人晚期实体瘤患者。 用于治疗既往接受过一线标准化疗后不可耐受的局部晚期或转移性食管鳞状细胞癌患者。 用于一线治疗复发或转移性鼻咽癌患者。 2023年2月24日,Tislelizu...
3 Recruiting Treatment Colorectal Cancer / Microsatellite Instability-high (MSI-H) 1 somestatus stop reason just information to hide 3 Recruiting Treatment Esophageal Squamous Cell Carcinoma (ESCC) 1 somestatus stop reason just information to hide 3 Recruiting Treatment Esophagus Adenocarcinoma / Gastro-...
2022年3月11日,百济神州PD-1抑制剂替雷利珠单抗正式获得中国药品监督管理局(NMPA)批准,用于治疗既往经治、局部晚期不可切除MSI-H/dMMR实体瘤患者。 2022年4月8日,由百济神州公司自主研发生产的替雷利珠单抗(商品名:百泽安®)正式获得国家药品监督管理局(NMPA)批准用于治疗既往接受过一线标准化疗后进展或不可耐受...
5、2022年1月5日:治疗接受铂类化疗后出现疾病进展的二或三线局部晚期或转移性非小细胞肺癌(NSCLC)患者 6、2022年3月11日:治疗既往经治、局部晚期不可切除或转移性高度微卫星不稳定型(MSI-H)或错配修复缺陷型(dMMR)实体瘤患者 7、2022年4月13日:治疗既往接受过一或二线标准化疗后进展或不可耐受的局部晚期或...
Whether immunotherapy biomarkers in previous studies (TMB, MSI, PD-L1, etc.) have equivalent predictive value for G/GEJ remains to be verified. In this phase II clinical trial of tislelizumab in combination with chemotherapy, potential therapy-related biomarkers in tumor samples, and changes in...
These patients should receive immunotherapy regardless of their PD-L1 expression status, as tumors with MSI-H status are known to be responsive to treatment with PD-1 inhibitors [15]. In response to the FDA ODAC recommendations, we evaluated PD-L1 further as a predictive biomarker of the ...
Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889); and Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986). ...
(TIS), an anti-PD-1 antibody, was generally well tolerated and demonstrated a clinically meaningful improvement in the objective response rate (ORR) in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient...
2022年3月11日,百济神州PD-1抑制剂替雷利珠单抗正式获得中国药品监督管理局(NMPA)批准,用于治疗既往经治、局部晚期不可切除MSI-H/dMMR实体瘤患者。 2022年4月8日,由百济神州公司自主研发生产的替雷利珠单抗(商品名:百泽安®)正式获得国家药品监督管理局(NMPA)批准用于治疗既往接受过一线标准化疗后进展或不可耐受...